Effect of KRN7000 on induced graft-vs-host disease

Experimental Hematology

Volumn 32, Issue 7, 2004, Pages 630-637

  Morecki, Shoshana ^a   Panigrahi, Soumya ^a   Pizov, Galina ^a   Yacovlev, Elena ^a   Gelfand, Yael ^a   Eizik, Osnat ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL FUNCTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE TRANSFER; MIXED LYMPHOCYTE REACTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CROSSES, GENETIC; FEMALE; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; GRAFT VS HOST DISEASE; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

MURINAE;

EID: 3042799925     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2004.04.005     Document Type: Article

References (45)

1. Yamaguchi Y., Motoki K., Ueno H., et al. Enhancing effects of (2S, 3S, 4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1, 3, 4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol Res. 8:1996;399-407
2. + natural killer T cells activated by α-galactosylceramide (KRN7000) have cytotoxic anti-tumor activity through mechanisms distinct from T cells and natural killer cells. Immunology. 99:2000;229-234
3. Kawano T., Cui J., Koezuka Y., et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science. 278:1997;1626-1629
4. + NK T lymphocytes. J Immunol. 161:1998;3271-3281
5. Singh N., Hong S., Scherer D.C., et al. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol. 163:1999;2373-2377
6. Hong S., Wilson M.T., Serizawa I., et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 9:2001;1052-1056
7. Thomas E.D. Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol. 1:1983;517-531
8. Sullivan K.M., Weiden P.L., Storb S., et al. Influence of acute and chronic graft-vs-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 73:(6):1989;1720-1728. Erratum in: Blood. 1989;74:1180
9. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-vs-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555-562
10. Slavin S., Naparstek E., Nagler A., Kapelushnik Y., Ackerstein A., Or R. Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT. Blood. 87:1996;4011-4014
11. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465
12. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 343:2000;750-758
13. Slavin S. Cancer immunotherapy with alloreactive lymphocytes. N Engl J Med. 343:2000;802-803
14. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncol. 2:2001;491-498
15. Slavin S., Morecki S., Eeiss L., Or R. Donor lymphocyte infusion: the use of allroeactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res. 11:2002;265-276
16. Cohen P., Vourka-Karussis U., Weiss L., Slavin S. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol. 151:1993;4803-4810
17. Morecki S., Yacovlev E., Diab A., Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 58:1998;3891-3895
18. Morecki S., Yacovlev E., Gelfand Y., Uzi I., Slavin S. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother. 24:2001;114-121
19. Brossay L., Chioda M., Burdin N., et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 188:1998;1521-1528
20. Kaplan E. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 53:1957;457-481
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170
22. Miyamoto K., Miyake S., Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:2001;531-534
23. Moodycliffe A.M., Nghiem D., Clydesdale G., Ullrich S.E. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol. 1:2000;521-525
24. Korngold R., Sprent J. Graft-vs-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med. 197:1991;12-18
25. Palathumpat V., Dejbakhsh-Jones S., Holm B., Strober S. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-vs-host disease. J Immunol. 149:1992;808-817
26. +) T cells which promote tolerance induction and regulate autoimmunity. Immunol Rev. 149:1996;217-230. [Review.]
27. + lymphoid engraftment. J Immunol. 152:1994;1004-1013
28. + T cells reciprocally regulate acute graft vs host disease. J Exp Med. 189:1999;1073-1081
29. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med. 187:1998;1047-1056
30. Sharif S., Arreaza G.A., Zucker P., et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 7:2001;1057-1062
31. Ferrara J.L. Cytokine inhibitors and graft-vs-host disease. Ann NY Acad Sci. 770:1995;227-236
32. Seino K., Yanagisawa L., Taniguchi H., et al. The effect of α-galactosylceramide upon allogenic rejection. Transplant Proc. 33:2001;437-438
33. Seino K.I., Fukao K., Muramoto K., et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci U S A. 98:2001;2577-2581
34. + Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest. 105:2000;1761-1767
35. Prigozhina T.B., Gurevitch O., Slavin S. Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol. 27:1999;1503-1510
36. Nikolic B., Lee S., Bronson R.T., Grusby M.J., Sykes M. Th1 and Th2 mediate acute graft-vs-host disease, each with distinct end-organ targets. J Clin Invest. 105:2000;1289-1298
37. Nakagawa R., Motoki K., Ueno H., et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an α-galactosylceramide, KRN7000. Cancer Res. 58:1998;1202-1207
38. Metelitsa L.S., Naidenko O.V., Kant A., et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 167:2001;3114-3122
39. Crowe N.Y., Smyth M.J., Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med. 196:2002;119-127
40. Morecki S., Slavin S. Toward amplification of a graft-vs-leukemia effect while minimizing graft-vs-host disease. J Hematother Stem Cell Res. 9:2000;355-366. [Review.]
41. + immune regulatory cells inhibits graft-vs-host disease lethality. Blood. 99:2002;3493-3499
42. Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-vs-leukemia. Science. 276:1997;1719-1724
43. Tiberghien P., Ferrand C., Lioure B., et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 97:2001;63-72
44. Litvinova E., Maury S., Boyer O., et al. Graft-vs-leukemia effect after suicide-gene-mediated control of graft-vs-host disease. Blood. 100:2002;2020-2025
45. Drobyski W.R., Gendelman M. Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. Leuk Lymphoma. 43:2002;2011-2016